Cancer situation in China: an analysis based on the global epidemiological data released in 2024

IF 20.1 1区医学 Q1 ONCOLOGY Cancer Communications Pub Date : 2024-12-10 DOI:10.1002/cac2.12627

Xiayao Diao, Chao Guo, Yukai Jin, Bowen Li, Xuehan Gao, Xin Du, Zhenchong Chen, Minju Jo, Yi Zeng, Chao Ding, Wenwu Liu, Jianrong Guo, Shanqing Li, Haibo Qiu

{"title":"Cancer situation in China: an analysis based on the global epidemiological data released in 2024","authors":"Xiayao Diao, Chao Guo, Yukai Jin, Bowen Li, Xuehan Gao, Xin Du, Zhenchong Chen, Minju Jo, Yi Zeng, Chao Ding, Wenwu Liu, Jianrong Guo, Shanqing Li, Haibo Qiu","doi":"10.1002/cac2.12627","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Cancer remains a major cause of mortality and a significant economic burden in China. Exploring the disparities in cancer patterns and control strategies between China and developed countries may offer valuable insights for policy formulation and enhance cancer management efforts. This study examined the incidence, mortality, and disability-adjusted life year (DALY) burden of cancer in China, and compared these metrics with those observed in the United States (US) and the United Kingdom (UK).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Data on cancer incidence, mortality, and DALYs for China, the US, and the UK were sourced from the GLOBOCAN 2022 online database and the Global Burden of Disease 2021 study (GBD 2021). We utilized Joinpoint regression models to analyze trends in cancer incidence and mortality across these countries, calculating annual percent changes (APCs) and determining the optimal joinpoints.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In 2022, China recorded around 4,824,703 new cancer cases and 2,574,176 cancer-related deaths, contributing to 71,037,170 DALYs. China exhibited a lower cancer incidence rate compared to the US and the UK. Although cancer-related mortality in China is slightly lower than that in the UK, it is significantly higher than that in the US. Additionally, China experienced significantly higher DALY rates compared to both the US and UK. The cancer landscape in China was also undergoing significant changes, with a rapid rise in the incidence and burden of lung, colorectal, breast, cervical, and prostate cancers. Meanwhile, the incidence and burden of stomach cancer continued to decline. Although the incidence of liver and esophageal cancers was decreasing, the burden of liver cancer was increasing, while the burden of esophageal cancer remained largely unchanged.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The cancer profile of China is shifting from that of a developing country to one more typical of a developed country. The ongoing population aging and the rise in unhealthy lifestyles are expected to further escalate the cancer burden in China. Consequently, it is crucial for Chinese authorities to revise the national cancer control program, drawing on successful strategies from developed countries, while also accounting for the regional diversity in cancer types across China.</p>\n </section>\n </div>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"45 2","pages":"178-197"},"PeriodicalIF":20.1000,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cac2.12627","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Communications","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cac2.12627","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Cancer remains a major cause of mortality and a significant economic burden in China. Exploring the disparities in cancer patterns and control strategies between China and developed countries may offer valuable insights for policy formulation and enhance cancer management efforts. This study examined the incidence, mortality, and disability-adjusted life year (DALY) burden of cancer in China, and compared these metrics with those observed in the United States (US) and the United Kingdom (UK).

Methods

Data on cancer incidence, mortality, and DALYs for China, the US, and the UK were sourced from the GLOBOCAN 2022 online database and the Global Burden of Disease 2021 study (GBD 2021). We utilized Joinpoint regression models to analyze trends in cancer incidence and mortality across these countries, calculating annual percent changes (APCs) and determining the optimal joinpoints.

Results

In 2022, China recorded around 4,824,703 new cancer cases and 2,574,176 cancer-related deaths, contributing to 71,037,170 DALYs. China exhibited a lower cancer incidence rate compared to the US and the UK. Although cancer-related mortality in China is slightly lower than that in the UK, it is significantly higher than that in the US. Additionally, China experienced significantly higher DALY rates compared to both the US and UK. The cancer landscape in China was also undergoing significant changes, with a rapid rise in the incidence and burden of lung, colorectal, breast, cervical, and prostate cancers. Meanwhile, the incidence and burden of stomach cancer continued to decline. Although the incidence of liver and esophageal cancers was decreasing, the burden of liver cancer was increasing, while the burden of esophageal cancer remained largely unchanged.

Conclusions

The cancer profile of China is shifting from that of a developing country to one more typical of a developed country. The ongoing population aging and the rise in unhealthy lifestyles are expected to further escalate the cancer burden in China. Consequently, it is crucial for Chinese authorities to revise the national cancer control program, drawing on successful strategies from developed countries, while also accounting for the regional diversity in cancer types across China.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

中国癌症状况：基于2024年全球流行病学数据的分析

背景：在中国，癌症仍然是导致死亡的主要原因，也是一个重要的经济负担。探讨中国与发达国家在癌症模式和控制策略上的差异，可以为政策制定和加强癌症管理工作提供有价值的见解。本研究调查了中国癌症的发病率、死亡率和残疾调整生命年（DALY）负担，并将这些指标与美国和英国的观察结果进行了比较。方法：中国、美国和英国的癌症发病率、死亡率和DALYs数据来自GLOBOCAN 2022在线数据库和全球疾病负担2021研究（GBD 2021）。我们利用连接点回归模型分析了这些国家癌症发病率和死亡率的趋势，计算了年变化百分比（apc）并确定了最佳连接点。结果：2022年，中国记录了约4,824,703例新发癌症病例和2,574,176例癌症相关死亡，贡献了71,037,170 DALYs。与美国和英国相比，中国的癌症发病率较低。虽然中国的癌症相关死亡率略低于英国，但明显高于美国。此外，与美国和英国相比，中国的DALY率要高得多。中国的癌症格局也发生了重大变化，肺癌、结直肠癌、乳腺癌、宫颈癌和前列腺癌的发病率和负担迅速上升。同时，胃癌的发病率和负担持续下降。虽然肝癌和食管癌的发病率在下降，但肝癌的负担在增加，食管癌的负担基本保持不变。结论：中国的癌症状况正在从一个发展中国家转变为一个更典型的发达国家。持续的人口老龄化和不健康生活方式的增加预计将进一步加剧中国的癌症负担。因此，至关重要的是，中国当局要修改国家癌症控制计划，借鉴发达国家的成功战略，同时也要考虑到中国癌症类型的地区多样性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Communications Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

25.50

自引率

4.30%

发文量

153

审稿时长

4 weeks

期刊介绍： Cancer Communications is an open access, peer-reviewed online journal that encompasses basic, clinical, and translational cancer research. The journal welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics.